Ruggedness of Visible-Residue Limits for Cleaning (Part II) - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Ruggedness of Visible-Residue Limits for Cleaning (Part II)
The author challenges current detection methodologies.

Pharmaceutical Technology
Volume 35, Issue 3, pp. 122-128

Table I: Residue target concentrations.
Determinations of VRLs consistently followed the same manner of presentation for the observers. The arrangement of the soiled coupons began with the ARL, which was the lower of either the health-based limit or the adulteration-based limit (4 g/cm2 ). Residue levels decreased sequentially with a solvent blank as the last sample. The observers viewed all of the sample soils as a single group. For the majority of samples (133 of 200 = 67%), the lowest spotted residue was visible for the observers. The VRL was reported as less than the lowest residue concentration. This report resulted in a refinement of the sample preparation. The updated residue preparation, as shown in Table I, targeted lower concentrations to determine the actual VRL and provide more accurate program data. With this refinement, the observers continued to visually detect the lowest residue limit in the majority of tested compounds.

Table II: Compound visible-residue limits (VRLs)
An alternative arrangement of the residue soils was considered to determine whether presenting the soiled coupons to the observers affected VRL determinations. This alternative arrangement consisted of a randomized presentation of several compounds at or near the determined VRL, including a number of blank coupons. The observers did not know beforehand the number of compounds tested or their concentrations, the number of soiled coupons, or the number of blanks in a 25 coupon array. A randomized coupon presentation is more scientifically justified and easier to defend.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here